LGST SEC filings, in plain English
Everything Semper Paratus Acquisition Corp has filed with the SEC that we hold — 40 filings, newest first, 6 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: Tevogen Inc. filed an 8-K reporting the results of its August 24, 2026 Annual Meeting of Stockholders and subsequent corporate actions. The filing details that stockholders approved an amendment to the Tevogen Inc. 2024 Omnibus Incentive Plan to increase available shares by 100,000,000 (Exhibit 10.1). It also reports that on August 26, 2026, the Company filed a Certificate of Amendment to its Certificate of Incorporation with the Delaware Secretary of State to permit stockholder action by written consent in lieu of a meeting (Exhibit 3.1). The document provides final vote counts for four proposals: election of Dr. Keow Lin Goh and Victor Sordillo as Class II directors; ratification of KPMG LLP as independent auditor; approval of the 2024 Plan Amendment; and approval of the Charter Amendment. Quorum was constituted by 5,956,141 shares out of 6,416,540 outstanding shares as of July 23, 2026. Why it matters: This filing confirms the governance structure and equity compensation capacity of Tevogen Inc., specifically the significant expansion of the incentive plan share pool and the procedural change allowing written consents. For investors tracking SPAC LGST (Semper Paratus Acquisition Corp), which is noted as CLOSED, this document reflects the post-business combination operational status of the merged entity, Tevogen Bio Holdings Inc., rather than any redemption or trust value changes associated with the SPAC itself.
What changed: The 10-Q filed under Commission file number 001-41002 is that of Tevogen Inc. (Nasdaq: TVGN, warrants exercisable at $575 per share) for the quarter ended June 30, 2026, with 6,511,540 shares outstanding as of August 10, 2026. Cash was $1,082,155 against $552,372 at December 31, 2025 and total assets $4,727,741, against total liabilities of $13,616,501 that include $2,829,264 of accounts payable, $1,651,000 of notes payable and a loan agreement balance grown to $6,400,000 from $4,400,000. The stockholders' deficit was $8,888,760 and the accumulated deficit $150,868,744. Why it matters: The company spends about $5.7 million a quarter against $1.1 million of cash, funding the gap with a loan that grew $2.0 million in six months, pre-funded warrants and at-the-market sales. The two preferred series carry $9.1 million of stated liquidation value ranking ahead of common on a balance sheet whose total assets are $4.7 million.
sponsor loans outstandingnothing moved · 1 with no prior record of ours
- Sponsor loans outstanding
- $6.4M · unchanged
The clause …“maturity dates ranging from February to March 2030. As of June 30, 2026, the outstanding balance on the Loan Agreement was $ 6,400,000 . As of June 30, 2026, $ 11,000,000 remained available for future financing. The Loan Agreement”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Tevogen Inc. — the successor to Semper Paratus Acquisition Corp, formerly Tevogen Bio Holdings — called its 2026 annual meeting for 24 August 2026, virtual, record date 23 July 2026. The proxy restates the deal history: the business combination under the 28 June 2023 merger agreement closed on 14 February 2024, and at closing the company paid SSVK Associates a $2.0 million Sponsor Advisory Services Fee for advisory services agreed in June 2023. The original sponsor converted all its Class B ordinary shares to Class A on 30 January 2023. Series B Preferred Stock is outstanding. Why it matters: The number that tells the story is the lock-up trigger: shares release only if the price holds $600.00 for 20 of 30 trading days. A threshold that size on a vehicle that IPO'd at $10 is the arithmetic of a large reverse split, i.e. the common has collapsed since the February 2024 close. Also on the record: a $2.0 million advisory fee paid to the sponsor's affiliate out of the closing, which is a direct transfer from the combined company to sponsor-side parties and belongs in Semper Paratus's sponsor track record.
What changed: 8-K of Tevogen Bio Holdings Inc. Item 5.03 (amendments to articles of incorporation or bylaws): on July 29, 2026 the Company filed a certificate of amendment changing its name to Tevogen Inc., effective July 30, 2026, and the Board approved a conforming bylaws amendment effective the same day with no other change to the Bylaws. The report states the name change does not affect the rights of security holders and that the CUSIP numbers remain 88165K200 for the common stock and 88165K119 for the public warrants. Why it matters: An identity change with no stated economic effect. The report says the common stock and the public warrants both continue to trade on the Nasdaq Global Market under the ticker symbol TVGN, giving two different securities the same symbol; that is recorded as filed and neither symbol is treated here as the warrant's.
What changed: Tevogen Bio Holdings Inc., the successor to Semper Paratus Acquisition Corp, filed the preliminary version of its 2026 annual meeting proxy, calling the meeting for August 24, 2026 at 1:30 p.m. ET with a July 23, 2026 record date. The statement recaps legacy SPAC terms: the Original Sponsor converted all Class B shares into Class A on January 30, 2023; the merger under the June 28, 2023 Merger Agreement closed February 14, 2024; and $2.0 million was payable to SSVK at closing as a Sponsor Advisory Services Fee. The lock-up releases only above $600.00 per share for 20 of 30 trading days. Why it matters: This is the preliminary filing that the definitive proxy of August 3, 2026 supersedes, so a reader should treat the definitive version as controlling — the meeting date, time and July 23, 2026 record date carried through unchanged. Its value is the legacy record it preserves for the Semper Paratus deal: the $2.0 million sponsor advisory fee paid at closing, the full conversion of the founder Class B class in January 2023, and a $600.00 lock-up release threshold far above any plausible trading level.
- What changed vs 2025-11-14sponsor loan $4.4M → $6.4M
sponsor loans outstanding1 moved
- Sponsor loans outstanding
- $4.4M$6.4M
SpacBrain reads this as the sponsor has advanced $2,000,000 more.
The clause …“maturity date ranging from February to March 2030. As of March 31, 2026, the outstanding balance on the Loan Agreement was $ 6,400,000 . As of March 31, 2026, $ 14,000,000 remained available for future financing. The Loan Agreement”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
sponsor loans outstandingnothing moved · 1 with no prior record of ours
- Sponsor loans outstanding
- not previously extracted$4.4M
The clause …“dates ranging from February to June 2029. As of December 31, 2025, the outstanding balance on the Loan Agreement was $ 4,400,000 . As of December 31, 2025, $ 18,000,000 remained available for future financing over the remaining”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Tevogen Bio Holdings Inc., the successor to Semper Paratus Acquisition Corporation, called a special meeting for 11:00 a.m. Eastern Time on February 19, 2026, held virtually, record date January 21, 2026. Proposal No. 2 asks holders to amend the certificate of incorporation to effect a reverse stock split. The company received a Nasdaq Notification on September 23, 2025 stating it was not in compliance with Listing Rule 5450(a)(1) because the average closing bid price of its stock had fallen below the required level. Why it matters: A Nasdaq bid-price deficiency dated September 23, 2025 that is still unresolved five months later, now addressed by a reverse split, tells holders the stock has traded below $1.00 for an extended period since the February 2024 de-SPAC. The split preserves the listing but not value. Unvested Tevogen Bio RSUs were converted into awards under the 2024 plan at closing, so that legacy equity continues to add to the share count being compressed.
sponsor loans outstandingnothing moved · 1 with no prior record of ours
- Sponsor loans outstanding
- $4.4M · unchanged
The clause …“dates ranging from February to June 2029 . As of September 30, 2025, the outstanding balance on the Loan Agreement was $ 4,400,000 . As of September 30, 2025, $ 21,000,000 remained available for future financing over the remaining”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.